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Those who do not learn from history are doomed 
to repeat it.1
Rickets, one of several ‘English diseases’, appeared during 
the Industrial Revolution when people moved into towns, 
summer sunshine was blocked by air pollution and many 
people worked indoors rather than outdoors, often from 
early childhood.2 Rickets was virtually abolished in the UK 
in World War II when cod liver oil supplements were 
offered to all pregnant and nursing mothers and children 
under five years of age3, and when parents ‘aired’ their 
babies outdoors. It took almost a century for the old 
wives tale (that cod liver oil cured rickets) to be 
confirmed, and the two forms of vitamin D (cholecalciferol 
and ergocalciferol), to be discovered.4 So how is it that 
increasing numbers of people have developed vitamin D 
deficiency-related rickets and osteomalacia, osteoporosis 
has worsened and falls and fragility fractures have become 
more common over recent decades? This is mainly 
because most of us spend less time outdoors as we work, 
play, socialise, travel and exercise indoors, behind glass 
windows that block transmission of ultraviolet light 
(UVB).  At the same time, we are advised to avoid midday 
sunshine in order to reduce skin cancer risks (and skin 
ageing) by seeking shade, covering up and using powerful 
sunscreens, especially for children. For the growing 
proportion of the UK population who are black or Asian, 
increased skin pigmentation reduces skin synthesis of 
vitamin D by UVB, and, the further north we live, the less 
available UVB there is. Thus, instead of making enough 
vitamin D ourselves, under tightly regulated feedback 
systems avoiding toxicity in normal people5, we are 
dependent on dietary or supplemental vitamin D, as a 
‘vitamin’, to avoid overt manifestations of vitamin D 
deficiency both in the UK and globally as the problem of 
deficiency becomes increasingly common in both sunny 
and temperate climates.6 
Those reading this debate in Scotland are even more 
likely to be vitamin D insufficient than readers in southern 
parts of the UK.7 The problem gets worse with age as skin 
synthesis and gut absorption of vitamin D become less 
efficient.8,9 This situation is also exacerbated in those with 
reduced mobility, loss of independence, and especially in 
those in residential care.10 There is a large body of 
evidence associating hypovitaminosis D with increased 
risks for many diseases, in virtually all systems of the body 
and not just in the musculoskeletal system. Serum 
25-hydroxyvitamin D (25[OH]D) is generally accepted as 
a measure of vitamin D repletion (status). The significance 
of this measurement in the investigation of disease relates 
to the fact that 25(OH)D is activated locally in target 
tissues, free of feed-back regulation. This local activation is 
directly dependent on serum 25(OH)D concentration, 
explaining the physiological significance of serum 25(OH)
D concentration for human health.11–13 
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These data cover associations and mechanisms for 
cardiovascular disease, innate and acquired immunity, 
infections, autoimmune disease (especially multiple 
sclerosis), inflammatory disorders and psoriasis. Higher 
vitamin D status is associated with reduced risks, cross-
sectionally and often prospectively, for these disorders, 
including melanoma, the most aggressive skin cancer and 
itself triggered by sunburn.14–21 However, randomised 
controlled trial (RCT) data indicating adequate 
supplementation with vitamin D for non-bony conditions 
is still insufficient to prove causality. For bone mineral 
density, muscle strength, falls and fragility fractures, 
intakes of at least 800 IU/day of vitamin D reduces risk, 
though massive doses may increase these risks 
temporarily.22–26 Thus, our evidence base supports the 
need to return to the situation achieved during World 
War II, when the reduction in vitamin D deficiency 
lowered the risks of rickets and osteomalacia; it does 
not however support the use of supplemental intakes 
(above 800 to 1000 IU/day) in the long-term in healthy 
people for reducing non-bony health risks. Indeed, 
history teaches us that other potential ‘magic bullets’ 
thought to reduce several major health risks can prove 
ineffective and may even increase those risks (e.g. RCTs 
using beta-carotene with vitamin A for prevention of 
lung cancer and heart disease).27 The problems with the 
use of beta-carotene probably resulted from confounding 
by other dietary factors; similar confounding by 
unidentified factors affecting vitamin D status cannot as 
yet be excluded.
These considerations contributed to the recent Institute 
of Medicine (IOM) recommendations from the US that 
dietary intakes in the population as a whole should reach 
400 IU/day in infants and children, 600 IU/day in adults 
and pregnant and nursing mothers, and 800 IU/day in 
older people (and by implication, others at increased risk 
of D deficiency, e.g. dark skinned, vegetarians and 
vegans28). Vitamin D deficiency is increasingly common 
worldwide and is known to increase infant mortality 
(from acute heart failure or hypocalcaemic fits),3 and is 
also associated with increased adult mortality.29 
Disagreement on defining ‘deficiency’ based on serum 
25(OH)D assays is common. Genetic variation in the 
vitamin D axis has a small independent effect on serum 
25(OH)D concentration, but the literature demonstrates 
a reasonable consensus that values of <50 nmol/l by any 
assay reflect a deficiency severe enough to lead to 
clinically obvious bone problems.30,12 Thus, in countries 
where this value is not reached by the majority of 
residents across all seasons of the year, the population 
should benefit, in bone health at least, from increasing 
vitamin D intakes to achieve 25(OH)D values of at least 
50 nmol/l. In the young, 25(OH)D concentrations above 
50 nmol/l increase bone density ‘dose-wise’, reducing 
bone risks in later life.32 Thus, 50 nmol/l is a serum 
25(OH)D target level likely to be raised as new evidence 
accrues. In Scotland, a recent report on post-menopausal 
women showed that they never reach a mean 25(OH)D 
concentration of 50 nmol/l at any season of the year.33 In 
winter, 40% of post-menopausal women in Surrey were 
deficient (10% of Caucasian and 65% of Asian women). In 
summer, 16% were deficient (0% of White and >50% of 
Asian women). Higher values, e.g. 75–110 nmol/l, are 
associated with health benefits in observational studies. 
At higher, but non-toxic, concentrations, however, there 
are suggestions of possible adverse effects that need 
further investigation.34,35 Better maternal vitamin D status 
improves bone health in children aged 9 years old,36 and 
other possible transgenerational effects require study. 
Vitamin D deficiency (25(OH)D <25 nmol/l) is found at 
all ages in the UK in 5–15% of Caucasian people. It rises 
to >20% in those aged between 19–24 years, increasing 
again after the age 60 and reaching >40% in people in 
their 80s. A lesser degree of deficiency (25(OH)D 
<50nmol/l) is never found in less than 20% of the 
Caucasian population at any age and is found in >40% of 
people over the age of 11 years old; in >60% of those 
aged between 19–24 years, and increases in over 65-year-
olds, peaking at >80% among those living in an institutional 
setting.37 This nationwide problem requires urgent 
attention. Preventative public health measures would be 
more cost-effective than medical management: provision 
of 400–800 IU/day using Healthy Start supplements costs 
less than £4/year (2010 prices) but one 25(OH)D assay 
costs £10.50–£25.3 The costs of modest food fortification 
would, as for other foods, be passed on to consumers. In 
Finland, voluntary food fortification with vitamin D has 
reduced the prevalence of vitamin D deficiency (25(OH)
D <50 nmol/l) significantly in most population groups.38,39 
This approach, already widely used in the USA and 
enforced by statute in the UK since 1942 (but only for 
margarine [at 280–350 IU/100G40]), requires care to 
avoid excessive intakes in infants.3 Ultraviolet B (UVB) 
irradiation of certain vegetables, notably mushrooms and 
yeast, increases vitamin D content and is used in some 
countries,3 and may prove more useful than trying to 
ensure controlled UVB irradiation of the skin. Surveys of 
representative population groups and checks on food 
content would be needed to audit the adequacy of 
provision and its safety at the population level. Such 
audits and safety checks would be expected to lead to 
adjustment of fortification levels where necessary. 
The many studies of vitamin D status in the UK over 
recent years have clearly not been acted upon, and this 
must change.41 Even modest risk reductions in 
musculoskeletal vitamin D deficiency disorders, acute 
neonatal heart failure, rickets, the severity and costs of 
osteoporosis and its painful complications, and in 
fragility fractures (in the 25,000 overt vertebral fractures 
and the 70,000 annual hip fractures in England and Wales 
which have a falling in-patient mortality but a continuing 
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mortality of 20% after six months and 30% by one year, 
with a 50% loss of independence42–45) would, clearly, be 
welcome to sufferers and their families and would also 
reduce NHS costs. At present, the NHS has no 
recommendations for vitamin D intake levels for those 
aged between 19 and 64 years old.3,37 Compliance with 
oral supplementation is well known to be poor (reducing 
to 50% after six months in those being treated for 
osteoporosis). In the UK supplements on prescription 
usually contain either calcium (which can cause 
constipation, reducing compliance and, in supplements, 
may increase cardiovascular risks47) or vitamin A which 
antagonises vitamin D.3,48 It would be helpful, therefore, if 
the British National Formulary (BNF) included 
preparations of vitamin D alone, at a range of doses, to 
facilitate treatment of people presenting clinically with 
deficiency related disorders. While many pregnant and 
nursing women might take supplements, as they do folic 
acid, others might not use them regularly, even if they 
could afford them, or even if they were free of charge 
for all. 
Thus, food fortification, adjusted to achieve serum 
25(OH)D concentrations across the healthy adult 
population of at least 50 nmol/l (but ideally <150 nmol/l) 
would provide a safe, acceptable and cost-effective way 
of reducing health risks from musculoskeletal disorders 
known to benefit from improved vitamin D intakes, with 
reduced fracture risks confirmed in corrected meta-
analysis of data for 68,500 patients in seven trials.49 This 
could be introduced while we await the outcomes of 
large scale RCTs currently in progress on the efficacy 
and safety of higher doses,50–51 before we can judge what 
is ‘not too little and not too much but just right'.52 
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It would be easy to assume, given the excited media 
coverage that vitamin D generates, that the case for 
universal supplementation was already proven. Vocal 
lobbying is however no substitute for scientific evidence, 
and for vitamin D, we do not have the understanding of 
its biological effects or the required evidence for the 
efficacy or safety of universal supplementation.
There are several major disease targets that vitamin D 
supplementation might potentially ameliorate – bone 
health, cancer, cardiovascular disease, autoimmune 
disease (including multiple sclerosis and type 1 diabetes) 
and metabolic disease including type 2 diabetes. What 
evidence do we have that supplementation at the 
population level would improve outcomes in these 
conditions?
Evidence for bone health is probably the strongest. 
Observational studies suggest that supplementation 
with low doses of vitamin D reduces the risk of rickets,1 
and in selected older people (particularly those in 
institutional care), calcium and vitamin D supplements 
reduce the risk of falls and osteoporotic fracture.2 
However, these benefits do not appear to extend to 
community-dwelling older people, even if they have had 
a previous fracture3, and the Women’s Health Initiative 
(WHI) trial4 did not show a significant reduction in hip 
fracture when supplementing a large, population-based 
cohort with low-dose vitamin D and calcium.
Although prospective observational data links low 
25-hydroxyvitamin D (25[OH]D) levels with an increased 
risk of cardiovascular events, supplementation trials 
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devised to specifically reduce the risk of cardiovascular 
events have not been performed. Meta-analysis of existing 
osteoporosis trials (which are clearly not representative 
of the general population) show no reduction in myocardial 
infarction or stroke,5 and the effect of supplementation 
on cardiovascular risk factors has been variable; some but 
not all studies show improvement in endothelial function 
(a powerful marker of cardiovascular risk),6–8 but there 
appears to be little effect on lipid levels, and blood 
pressure is modestly reduced only in those with elevated 
blood pressure at baseline.9
Data on cancer outcomes in supplementation trials is 
even scantier. The WHI trial showed no reduction in 
colorectal cancer,10 and the one trial frequently quoted 
to show an effect of vitamin D on cancer rates (again as 
a secondary analysis of an osteoporosis trial) actually 
showed a reduction in new cancers with calcium 
supplements, but no additional reduction when vitamin 
D was combined with calcium.11 Observational data are 
not easy to interpret; although there appears to be a 
lower cancer incidence with increasing 25(OH)D levels 
in most studies, a few studies show the opposite, albeit 
with better cancer survival with higher vitamin D levels.
Both type 1 and type 2 diabetes mellitus have been 
linked with lower 25(OH)D levels, but evidence that 
vitamin D supplementation can prevent the occurrence 
of type 1 diabetes is lacking, and the available evidence 
from randomised controlled trials does not suggest any 
effect on rates of type 2 diabetes to date.12 Even in 
patients with pre-existing diabetes or impaired fasting 
glucose, vitamin D supplements appear to produce only 
a small improvement in insulin resistance and fasting 
glucose – and no improvement in long-term glycaemic 
control. Once again, robust data from large, long-term 
trials are lacking.
The evidence base for other health conditions, for 
example multiple sclerosis, is even flimsier, with no 
intervention studies to guide practice. Several trials 
across a variety of populations at risk from a number of 
infections have now been performed to assess whether 
vitamin D supplementation can reduce infection rates, 
especially rates of respiratory tract infection and 
tuberculosis; results have been mixed at best, as 
confirmed by a recent systematic review.13
No large randomised controlled trials have been 
conducted to examine the effect of vitamin D 
supplementation on overall mortality in a general 
population; meta-analysis of existing trials (mostly for 
osteoporosis and fracture prevention) suggest either a 
small effect on mortality (absolute risk reduction of 
0.5%)14 or no effect.5 It cannot be assumed that any 
benefit in a group at such high risk of death as those 
with osteoporosis will apply to a general population.
What about potential harms? These are of particular 
importance in any population-level intervention, as large 
numbers of healthy people (i.e. with little scope for 
accruing benefits) will receive exposure to the potential 
harm. It is unlikely that universal supplementation will 
cause overt toxicity; the doses required for this appear 
to be very large indeed.15 However, the WHI trial4 
showed a 16% higher risk of renal and ureteric stones in 
the treatment group (who received only 400U of 
vitamin D3). Observational data point to higher 
immunoglobulin E (IgE) levels in people with 25(OH)D 
levels above 135 nmol/l,16 higher rates of atopic disorders 
in the offspring of women with 25(OH)D levels 
>75 nmol/l during pregnancy17 and two observational 
studies suggest a slightly higher risk of cardiovascular 
events in those with the highest 25(OH)D levels,18,19 
compared with people with moderate 25(OH)D levels. 
Finally, there is the concern that patients with primary 
hyperparathyroidism (often undiagnosed until a routine 
serum calcium level is checked) could suffer from 
elevated, and therefore potentially symptomatic, 
hypercalcaemia. Are these potential risks borne out in 
practice? Do they outweigh potential benefits at a 
population level? The truth is, we simply don’t know, and 
until we conduct the appropriate large-scale intervention 
trials, we will not know.
In conclusion, the benefits of universal supplementation 
are unproved, the risks are unknown, and we require 
further evidence before committing to such a public 
health intervention. Observational and in vitro studies 
are a poor guide here; let us not forget how vitamins C, 
E and beta-carotene moved from early promise to 
useless (and indeed potentially harmful) interventions;20 
witness the failure of B group vitamins to improve 
vascular outcomes, and compare the current controversy 
surrounding folate supplementation and cancer risk. 
What is good for one group may also not be good for 
all; we need to evaluate and tailor the balance of benefit 
and risk for each group of people that we care for. To 
supplement the entire population with vitamin D in the 
absence of good data that the benefits outweigh the 
risks for each individual would be poor medicine and an 
abrogation of our duty of care to individuals.
BJ Boucher, MD Witham
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